Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors

DNA damage-induced ATM- and Rad-3-related (ATR) kinase activation in non-replicating cells is regulated by the XPB subunit of transcription factor IIH (TFIIH)

(2017) Michael G. Kemp   JOURNAL OF BIOLOGICAL CHEMISTRY

AZD6738, A Novel Oral Inhibitor of ATR, Induces Synthetic Lethality with ATM Deficiency in Gastric Cancer Cells

(2017) Ahrum Min et al.   MOLECULAR CANCER THERAPEUTICS

Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer

(2017) Di Zhao et al.   NATURE

PGBD5 promotes site-specific oncogenic mutations in human tumors

(2017) Anton G Henssen et al.   NATURE GENETICS

PARP inhibitors enhance replication stress and cause mitotic catastrophe in MYCN-dependent neuroblastoma

(2017) V Colicchia et al.   ONCOGENE

CHK1 as a therapeutic target to bypass chemoresistance in AML

(2016) Laure David et al.   Science Signaling

Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models ofMLL-rearranged AML

(2016) Isabel Morgado-Palacin et al.   Science Signaling

Efficacy of ATR inhibitors as single agents in Ewing sarcoma

(2016) Maria Nieto-Soler et al.   Oncotarget

CHK1 as a therapeutic target to bypass chemoresistance in AML

(2016) Laure David et al.   Science Signaling

Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models ofMLL-rearranged AML

(2016) Isabel Morgado-Palacin et al.   Science Signaling

ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells

(2015) M. Kwok et al.   BLOOD

Molecular Pathways: Targeting ATR in Cancer Therapy

(2015) L. M. Karnitz et al.   CLINICAL CANCER RESEARCH

Drugging ATR: progress in the development of specific inhibitors for the treatment of cancer

(2015) Kevin M Foote et al.   Future Medicinal Chemistry

Synthetic lethality in chronic lymphocytic leukaemia with DNA damage response defects by targeting the ATR pathway

(2015) Marwan Kwok et al.   LANCET

Alternative NHEJ Pathway Components Are Therapeutic Targets in High-Risk Neuroblastoma

(2015) Erika A. Newman et al.   MOLECULAR CANCER RESEARCH

Alternative lengthening of telomeres renders cancer cells hypersensitive to ATR inhibitors

(2015) R. L. Flynn et al.   SCIENCE

PI3K/AKT signaling modulates transcriptional expression of EWS/FLI1 through specificity protein 1

(2015) Chiara Giorgi et al.   Oncotarget

Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition

(2015) Fiona K. Middleton et al.   Oncotarget

The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancer in vivo

(2015) Frank P. Vendetti et al.   Oncotarget

Machine-based method for multiplex in situ molecular characterization of tissues by immunofluorescence detection

(2015) Dmitry Yarilin et al.   Scientific Reports

Genomic DNA transposition induced by human PGBD5

(2015) Anton G Henssen et al.   eLife

A Synthetic Lethal Screen Identifies DNA Repair Pathways that Sensitize Cancer Cells to Combined ATR Inhibition and Cisplatin Treatments

(2015) Kareem N. Mohni et al.   PLoS One

ATR Pathway Inhibition Is Synthetically Lethal in Cancer Cells with ERCC1 Deficiency

(2014) K. N. Mohni et al.   CANCER RESEARCH

Cisplatin in cancer therapy: Molecular mechanisms of action

(2014) Shaloam Dasari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Platinum compounds in children with cancer

(2013) Antonio Ruggiero et al.   ANTI-CANCER DRUGS

Rhabdoid Tumors: An Initial Clue to the Role of Chromatin Remodeling in Cancer

(2013) Ryan S. Lee et al.   BRAIN PATHOLOGY

Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein Kinase with Monotherapy in Vivo Antitumor Activity

(2013) Kevin M. Foote et al.   JOURNAL OF MEDICINAL CHEMISTRY

Current and Future Strategies for Relapsed Neuroblastoma

(2013) Daniel A. Morgenstern et al.   JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY

ATR kinase activation in G1 phase facilitates the repair of ionizing radiation-induced DNA damage

(2013) Armin M. Gamper et al.   NUCLEIC ACIDS RESEARCH

DNA Damage Sensing by the ATM and ATR Kinases

(2013) A. Marechal et al.   Cold Spring Harbor Perspectives in Biology

An Animal Model of MYC-Driven Medulloblastoma

(2012) Yanxin Pei et al.   CANCER CELL

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment

(2012) Till Milde et al.   JOURNAL OF NEURO-ONCOLOGY

Novel mutations target distinct subgroups of medulloblastoma

(2012) Giles Robinson et al.   NATURE

Passenger deletions generate therapeutic vulnerabilities in cancer

(2012) Florian L. Muller et al.   NATURE

Autocrine activation of the MET receptor tyrosine kinase in acute myeloid leukemia

(2012) Alex Kentsis et al.   NATURE MEDICINE

Paracrine Signaling Through MYCN Enhances Tumor-Vascular Interactions in Neuroblastoma

(2012) Y. H. Chanthery et al.   Science Translational Medicine

Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation

(2012) E Fokas et al.   Cell Death & Disease

Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

(2011) Jean-Damien Charrier et al.   JOURNAL OF MEDICINAL CHEMISTRY

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

(2011) Philip M Reaper et al.   Nature Chemical Biology

Challenging issues in pediatric oncology

(2011) Ching-Hon Pui et al.   Nature Reviews Clinical Oncology

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

The Mechanism of Double-Strand DNA Break Repair by the Nonhomologous DNA End-Joining Pathway

(2010) Michael R. Lieber   Annual Review of Biochemistry

A Genome-wide Camptothecin Sensitivity Screen Identifies a Mammalian MMS22L-NFKBIL2 Complex Required for Genomic Stability

(2010) Brenda C. O'Connell et al.   MOLECULAR CELL

A minority of foci or pan-nuclear apoptotic staining of  H2AX in the S phase after UV damage contain DNA double-strand breaks

(2010) S. de Feraudy et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2

(2009) Andrea Beucher et al.   EMBO JOURNAL

Dose-Intensified Compared With Standard Chemotherapy for Nonmetastatic Ewing Sarcoma Family of Tumors: A Children's Oncology Group Study

(2009) Linda Granowetter et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion

(2009) S. E. Golding et al.   MOLECULAR CANCER THERAPEUTICS

A mouse model of ATR-Seckel shows embryonic replicative stress and accelerated aging

(2009) Matilde Murga et al.   NATURE GENETICS

Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers

(2009) Peter C. Fong et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expression of the TrkA or TrkB receptor tyrosine kinase alters the double-strand break (DSB) repair capacity of SY5Y neuroblastoma cells

(2008) J SCHULTE et al.   DNA REPAIR

AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies

(2008) S. D. Zabludoff et al.   MOLECULAR CANCER THERAPEUTICS

ATR: an essential regulator of genome integrity

(2008) Karlene A. Cimprich et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

Complementary functions of ATM and H2AX in development and suppression of genomic instability

(2008) S. Zha et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA